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This phase II study assessed the safety and efficacy of oxaliplatin and capecitabine in patients with advanced oesophageal cancer. Fifty-
one eligible patients received oxaliplatin 130mgm
 2 intravenously on day 1 and capecitabine 1000mgm
 2 orally twice daily on days
1 to 14 in a 21-day treatment cycle as first-line treatment for advanced oesophageal cancer. Grade 3 neutropenia was seen in one
patient and anaemia in another patient. No grade 4 haematological toxicities were observed. Grade 4 non-haematological toxicity
(lethargy) occurred in one patient (2%). Grade 3 non-haematological toxicity was seen in 14 (27%) patients (vomiting and
polyneuropathy (8%); nausea (6%); lethargy and hand–foot syndrome (4%); and anorexia, diarrhoea, and hyperbilirubinaemia (each
in one patient)). In 22% of the patients, toxicity was the reason for stopping the treatment. The overall response rate was 39%. The
median overall survival was 8 months; the 1-year survival rate was 26%. In the quality of life (QoL) analysis, the emotional well-being
improved during treatment, but the physical functioning scores declined. The fatigue score on the symptom scales increased. Overall,
the global QoL score did not change during treatment. In conclusion, the activity of oxaliplatin and capecitabine is comparable with
other chemotherapy regimens in advanced oesophageal cancer with a low frequency of grade 3/4 toxicity. Because this treatment
can be given on an outpatient basis, it is probably less toxic than cisplatin-based therapy and preserves QoL during treatment, it is a
viable treatment option in patients with advanced oesophageal cancer.
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Patients with oesophageal cancer generally have a poor prognosis,
because the majority of them already have locally unresectable or
metastatic disease at presentation. Furthermore, even after surgery
with curative intent, local recurrences and/or distant metastases
are detected in approximately two-thirds of the patients within 5
years of follow-up (Hofstetter et al, 2002). Many patients with
oesophageal cancer require palliative therapy to treat symptoms,
such as dysphagia. Placement of a self-expanding metal stent,
external beam radiotherapy, intraluminal radiotherapy (brachy-
therapy), and laser therapy are commonly used palliative
modalities to treat dysphagia (Homs et al, 2005).
Palliative chemotherapy may result in local and distant tumour
and symptom control. The effect of chemotherapy on survival is
unclear, mainly owing to a lack of randomised trials. The most
frequently used chemotherapy regimen for patients with metastatic
disease is a combination of 5-fluorouracil and cisplatin, with
response rates ranging from 15–45% (Ilson, 2003). However,
treatment with 5-fluorouracil and cisplatin can induce severe
toxicity (Bleiberg et al, 1997). Besides, most patients have to be
hospitalised for this treatment. In two trials, a significant positive
effect of chemotherapy on quality of life (QoL) and/or overall
survival was demonstrated (Webb et al, 1997; Ross et al, 2002).
However, in both trials, patients with oesophageal and gastric
cancer (predominantly adenocarcinomas) were treated. There are
no studies comparing the effect of chemotherapy and other
palliative treatments on symptom control (e.g. dysphagia).
Capecitabine is a novel oral fluoropyrimidine carbamate, which
is converted into 5-fluorouracil, preferentially in tumours. Clinical
studies with capecitabine have been predominantly performed in
colorectal and breast cancer. In a study performed by Hoff et al
(2001) in patients with advanced colorectal cancer, treatment with
capecitabine was at least as effective as treatment with 5-
fluorouracil plus leucovorin, but leaded to less hospitalisations
for adverse reactions. Swallowing tablets might be a problem in
patients with oesophageal cancer. However, it is our experience
that patients with grade 1 or 2 dysphagia are still able to ingest
tablets. Patients with grade 3 or 4 dysphagia are usually first
palliated with either a stent or brachytherapy and are thereafter
nearly always able to ingest tablets.
The response rate of single-agent cisplatin in metastatic
oesophageal cancer is 6–26% (Kok, 1997), whereas that of
carboplatin is less than 10% (Sternberg et al, 1985; Mannell and
Winters (1989)). Oxaliplatin is a third-generation platinum
compound. It forms inter- and intrastrand cross-links with DNA.
These cross-links inhibit DNA replication and transcription. It has
demonstrated synergy with 5-fluorouracil in advanced colorectal
cancer (de Gramont et al, 2000; Giacchetti et al, 2000).
The combination of oxaliplatin and capecitabine has been tested
in several phase II studies in patients with metastatic colorectal
cancer (Borner et al, 2002; Cassidy et al, 2004). Grade 3/4
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capecitabine 1250mgm
 2 twice daily and oxaliplatin 130mgm
 2
in the study performed by Borner et al (2002). Cassidy et al (2004)
reported grade 3/4 diarrhoea in 16% of the patients treated with
oxaliplatin 130mgm
 2 and capecitabine 1000mgm
 2 twice daily.
The response rate was comparable, 49 and 55%, respectively.
Therefore, a capecitabine dose of 1000mgm
 2 twice daily on days
1 to 14 in combination with oxaliplatin 130mgm
 2 on day 1 in a
21-day treatment cycle is the recommended dose.
Based on these favourable results of oxaliplatin combined with
capecitabine in other gastrointestinal malignancies, we conducted
the present phase II study to evaluate the safety and efficacy of the
combination of oxaliplatin and capecitabine in patients with
metastatic or local–regional unresectable carcinoma of the
oesophagus, oesophagogastric junction, and cardia. In addition,
to evaluate the effects of this schedule on the patients’ well-being,
we performed a QoL analysis on these patients during the
treatment.
METHODS
Eligibility criteria
Eligible patients had histologically proven metastatic or local–
regional unresectable carcinoma of the oesophagus or gastric
junction and at least one unidimensionally measurable lesion
X20mm using conventional computed tomography (CT) or
magnetic resonance imaging scan or X10mm using spiral CT
scan had to be present. No prior chemotherapy for locally
advanced or metastatic disease was allowed. Patients were required
to be aged at least 18 years, to have an Eastern Cooperative
Oncology Group performance status of p2 and a life expectancy of
X3 months. Other criteria included adequate haematological,
renal, and hepatic functions as defined by: granulocyte count of at
least 1500mm
 3 and platelet count 100000mm
 3; serum creati-
nine p1.25 the upper normal limit (ULN); aspartate amino-
transferase and alanine aminotransferase p3 ULN (p5 ULN
in case of liver metastases) and bilirubin p1.25 ULN. Previous
neoadjuvant treatment for non-metastatic disease was allowed if
completed at least 6 months before the initiation of study
treatment. No history of malignancy, apart from non-melanoma-
tous skin cancer, curatively treated carcinoma in situ of the cervix,
or a ‘cured’ malignancy more than 5 years before enrolment was
allowed. Patients with evidence of central nervous system
metastases, a lack of physical integrity of the upper gastrointestinal
tract, a malabsorption syndrome, or an inability to take oral
medication were excluded. Patients were not eligible if they had a
pre-existing motor or sensory neurotoxicity 4 grade 1 according
to the National Cancer Institute Common Toxicity Criteria (NCI-
CTC version 3). The Ethics Committee at Erasmus University
Medical Centre approved the study and written informed consent
was obtained.
Treatment
Treatment consisted of oxaliplatin 130mgm
 2 intravenously on
day 1 and capecitabine 1000mgm
 2 orally twice daily on days 1–
14 (28 doses), repeated every 3 weeks. Oxaliplatin diluted in 250ml
of 5% glucose was administered as a continuous infusion over 2h.
Capecitabine had to be ingested with water every 12h, approxi-
mately 30min after a meal, starting at the evening of day 1.
Prophylactic anti-emetic use of a 5-HT 3 antagonist and
dexamethason was given. All patients continued either with
metoclopramide, domperidone, steroids, or 5-HT 3 antagonists.
Dose modifications were made for toxicity, using the NCI-CTC
(version 3). The absolute neutrophil count and the platelet count
had to be recovered to the required pre-treatment values before
start of the next treatment cycle. Non-haematological toxicity had
to be p grade 1 before start of every treatment cycle. If these
conditions were not met, dosing was delayed for a maximum of 2
weeks. If haematological or non-haematological toxicity was not
recovered to grade 1 or less after 2 weeks, patients were taken off-
study.
Persistent (X14 days) paresthesia or temporary (7–14 days)
painful paresthesia or functional impairment prompted a 25%
dose reduction of oxaliplatin. In case of persistent (X14 days)
painful paresthesia or functional impairment, oxaliplatin had to be
omitted until recovery and had to be restarted at 50% of the dose.
Patients went off-study if these toxicities recurred despite the dose
reductions.
Capecitabine was reduced with 25% in case of grade 2
hand—foot syndrome. In case of grade 2–4 diarrhoea, capecita-
bine intake had to be interrupted immediately. Standard treatment
for diarrhoea was prescribed (i.e. loperamide). The omitted doses
were not permitted to be administered after resuming treatment
and the total length of capecitabine treatment period was not
allowed to exceed 14 days. If patients experienced severe
capecitabine-related toxicity (4grade 2) despite two dose
reductions, necessitating discontinuation of treatment with
capecitabine, patients were taken off-study.
Patients who showed no disease progression and/or prohibitive
toxicity continued treatment for six courses, with a maximum of
eight courses in case of ongoing response.
Pre-treatment and follow-up evaluation
Pre-treatment evaluation included a detailed history taking, a
physical examination, and routine blood examinations. All
patients underwent a baseline CT of the chest and upper abdomen.
After discontinuation of treatment, follow-up visits were done
every 3 months to document late toxic effects, disease progression,
and survival.
Evaluation of response and toxicity
Patients were evaluable for response after two courses of
chemotherapy. Evaluation of response was done every other
course of chemotherapy. However, if tumour progression was
found at any time after randomisation, it was recorded as
progressive disease. Tumour response was assessed according to
the Response Evaluation Criteria In Solid Tumours (UICC, 2002).
The duration of response was measured from the time of complete
or partial response until the first date of recurrent or progressive
disease. Stable disease was measured from the start of treatment
until the criteria for progression were met. Progression-free and
overall survival was documented from the time of patient
randomisation until tumour progression or death.
QoL assessment
Quality of life was measured using the EORTC QLQ-C30 (version
3.0) and QLQ-OES18 (Aaronson et al, 1993; Blazeby et al, 2003).
Questionnaires were filled in before therapy, after every other
cycle, and after completion of chemotherapy. Patients with missing
forms were excluded from the analysis of the absent assessment
point. Scores were calculated according to the guidelines, yielding
a range of 0–100. A higher score for a functional scale represents a
higher level of functioning. A higher score for a symptom scale/
item represents a higher level of symptomatology/problems
(Fayers et al (2001)). Because high dropout rates result in more
favourable scores among the remaining patients, comparisons
were only made between baseline and after the second course and
between baseline and after stopping chemotherapy.
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An optimal two-stage design for phase II trials as described by
Simon was used (Simon, 1989). In the first stage, a total of 13
patients were included and at least four responses were required to
continue to the second stage. In the second stage, 30 additional
patients were included to a total sample size of at least 43. Thirteen
responses were needed to conclude with a 95% confidence that the
response rate was greater than 40%. Statistical differences in QoL
at different time points were determined using the t-test. All tests
were two sided at the .05 level of significance. The SPSS statistical
package (version 12.0; SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses.
RESULTS
Patient characteristics
From April 2003 to October 2005 51 patients were included in this
study. The baseline characteristics are summarised in Table 1. The
majority of the patients were male (86%) and most of them had
adenocarcinoma (88%).
Toxicity of and adherence to chemotherapy
The median number of treatment cycles was four (range 1–8).
Apart from progression of disease or end of protocol, reasons for
stopping chemotherapy were toxicity (22%), patient’s request
(4%), and clinical deterioration (2%). The dose of capecitabine was
reduced in five patients (10%), either because of diarrhoea (n¼3)
or hand–foot syndrome (n¼2). In four patients, the administra-
tion of capecitabine was prematurely interrupted because of
diarrhoea. The dose of oxaliplatin was reduced in three patients
because of painful paresthesia.
Haematological toxicity is summarised in Table 2. Apart from
one case each of grade 3 neutropenia and grade 3 anaemia, no
grade 3 or 4 haematological toxicities were observed. In the latter,
patient analysis showed an undetectable haptoglobin and an
increased LDH and bilirubin, indicating haemolysis, which has
been described in relation to oxaliplatin administration (Taleghani
et al, 2005).
Non-haematological toxicity is summarised in Table 2. Eighteen
patients were hospitalised during treatment. In eight patients, this
was directly related to the treatment (dehydration caused by
anorexia, nausea, vomiting, and/or diarrhoea (n¼6), grade 4
lethargy (n¼1), observation for one night in hospital after
laryngopharyngeal dysesthesia (n¼1)). In two patients, the
hospitalisation was possibly related to the treatment (venous
thromboembolism). The other eight hospitalisations were because
of disease-related problems, such as dysphagia requiring oeso-
phageal stenting, jaundice, ileus, pericarditis, fever, and tumour-
related bleeding.
Response
Forty-nine patients were evaluable for response. No complete
responses were seen. Nineteen patients (39%) achieved a partial
response, 21 patients (43%) had stable disease, and nine patients
(18%) had disease progression. The median duration of response
was 5.3 months (range 2–18).
Survival
All 51 patients were evaluable for survival. At the date of
evaluation (April 15, 2006) 43 patients have died. The median
survival time for all patients was 8 months (95% CI 6–9 months,
range 2–27 months). The 1-year overall survival was 26% and
2-year overall survival was 7%.
QoL
Hundred and forty-one of 165 expected questionnaires were
completed (85%). Four patients were excluded because QoL data
were not obtained before the start of treatment. The scores of the
responders were not different from the scores of the non-
responders.
From 41 patients we obtained the QLQ-C30 questionnaires at
baseline and after the second course, from 39 patients the OES18
questionnaires at these time points. Although the physical
functioning score declined significantly from 85 to 78 (P¼0.04),
the emotional functioning score improved significantly from 61 to
73 (P¼0.003). The other functional scores did not change. The
sleeping score of the EORTC QLQ-C30 decreased significantly
from 34 to 16 (P¼0.006), indicating improvement of sleeping. The
pain score from the EORTC QLQ-OES18 decreased significantly
from 16 to 9 (P¼0.045), indicating less pain. The score for dry
mouth increased significantly from 5 to 14 (0.005). No significant
changes were seen in the other symptom scores.
From 33 patients we obtained the QLQ-C30 questionnaires at
baseline and after stopping chemotherapy, from 31 patients the
OES18 questionnaires at these time points. Scores on the physical
functioning scale declined from 88 to 78 (P¼0.02), but scores on
the emotional functioning scale improved from 60 to 71 (P¼0.02).
From the symptom scales of the EORTC QLQ-C30, the sleeping
score decreased significantly from 34 to 17 (P¼0.03), indicating
less symptoms. However, the fatigue score increased significantly
from 30 to 43 (P¼0.003), indicating more fatigue. From the
symptom scales of the EORTC QLQ-OES18, the pain score
decreased significantly form 15 to 7 (P¼0.02), indicating less
pain. The dry-mouth score increased significantly from 5 to 20
(P¼0.01), indicating worsening of complaints from dry mouth.
No significant changes were seen in the other symptom scores.
Table 1 Baseline characteristics
No. %
Gender
Male 44 86
Female 7 14
Age (years)
Median 60
Range (31–76)
WHO
02 0 3 9
13 0 5 9
Missing 1 2
Weight loss
o5% 17 33
5–10% 17 33
410% 13 26
Missing 4 8
Histology
Adenocarcinoma 45 88
Squamous cell carcinoma 4 8
Undifferentiated carcinoma 2 4
Prior chemoradiotherapy/chemotherapy
Yes 6 12
No 45 88
Prior surgery
Transhiatal oesophagectomy 17 33
Laparotomy (without resection) 4 8
Sites of metastases
Lymph nodes 37
Liver 23
Lung 16
Locoregional recurrence 8
Other 8
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course and after stopping chemotherapy.
DISCUSSION
Our study showed no major haematological toxicity, except for
grade 3 anaemia in one patient and grade 3 neutropenia in another
patient. Grade 3 or 4 non-haematological toxicity was uncommon
as well. However, in 22% of the patients toxicity was the reason for
stopping the chemotherapy (grade 2 toxicity in seven out of 11
patients and grade 3 or 4 in four out of 11 patients). The most (in
more than 85% of the patients) reported toxicities were constitu-
tional, namely lethargy and polyneuropathy, but these were of mild
to moderate intensity. Other frequently (in more than 50% of the
patients) reported toxicities were gastrointestinal (nausea, vomit-
ing, and diarrhoea), which were also generally of mild to moderate
intensity. Although swallowing tablets might be a problem for
patients with oesophageal cancer, all patients in this study were
able to ingest the tablets.
These toxicities were comparable with that found in the study of
Cassidy et al (2004) in patients with metastatic colorectal cancer,
as were the reasons for withdrawal from therapy. In one other
phase II study, the combination of oxaliplatin and capecitabine
was tested as first-line treatment in patients with metastatic
adenocarcinoma of the oesophagus, gastro–oesophageal junction,
and gastric cardia (Jatoi et al, 2006). Grade 3 and 4 gastrointestinal
toxicity and lethargy were more common in this study,
neurological and haematological toxicities were not mentioned.
The toxicity prompted a dose reduction of capecitabine to
825mgm
 2, because of four treatment-related deaths. An explana-
tion for this difference in toxicity cannot be found, because the
baseline characteristics of the patients enrolled in both studies
seem to be comparable. However, these regional differences in
mainly gastrointestinal tolerability for fluoropyrimidines between
the United States and the rest of the world have been described
before (Haller et al, 2006). In another phase II study performed
in 54 patients with advanced gastric cancer (Park et al, 2006),
the toxicity of this regimen was comparable with the toxicity in
our trial.
Our study showed a median overall survival of 8 months, which
is in line with the results from other studies performed at our
institution in patients with metastatic or local–regional unresect-
able oesophageal cancer (Polee et al, 2003). However, the 1-year
survival in our study was slightly worse compared with that
observed in previous studies at our institution (26 vs 33%). This
might be explained by the fact that in our study more patients with
poor prognostic factors such as liver metastases were included (45
vs 23%). There were no differences in efficacy by tumour location,
histology, or prior preoperative chemo(radio)therapy (results not
shown). However, in view of the relatively small number of
included patients, such subset analyses must be interpreted with
caution.
Improving or maintaining QoL and achieving symptom relief
are important goals in the management of patients with metastatic
oesophageal cancer. In this study, patients reported an improve-
ment in emotional well-being after two courses of chemotherapy as
well as after stopping the chemotherapy. This is intriguing,
because the physical functioning scores declined significantly over
the same period. The reason for this decline in the physical
functioning scores is most probably caused by the increase of
fatigue, which was stated more frequently after stopping chemo-
therapy (median after four courses). This increase in fatigue
score may be owing to the treatment, but in about half of the
patients, the treatment was stopped because of disease progres-
sion, which can also lead to a higher level of fatigue. The
improvement of emotional well-being during chemotherapy
cannot be easily comprehended. Possibly, a better way of coping
with the diagnosis of incurable cancer throughout time leads to
this improvement. Second, the very act of undergoing treatment
may also lead to an improvement of emotional well-being. It has
been described that the QoL improves during chemotherapy,
despite considerable toxicity (Cunningham et al, 1998). Besides, it
is well known that patients are willing to undergo treatments that
have small benefits with major toxicity (Matsuyama et al, 2006).
Although the decrease of pain levels may be the effect of better
pain control by the use of analgesics (opioids as well as non-
opioids), it was observed that pain also decreased in patients with a
stable use of analgesics. In some patients, the dosages of analgesics
could be decreased or even stopped, suggesting an effect of the
chemotherapy.
Overall, the global QoL score at baseline did not change over
time. In the study of Ross et al (2002), the global QoL scores were
maintained with epirubicin/cisplatin/5-fluorouracil, but declined
with mitomycin/cisplatin/5-fluorouracil. In that study, the QoL
scores declined over time, but the follow-up of questionnaires was
longer than in our study (up to 1 year after treatment). In the study
of Webb et al (1997), the global QoL scores were maintained and
showed no difference between arms at 12 weeks (P¼0.71), but at
24 weeks the difference became more pronounced (P¼0.04), with
the epirubicin/cisplatin/5-fluorouracil scores maintained and the
5-fluorouracil/adriamycin/methotrexate scores lowered.
In conclusion, our study shows that the activity of the
combination of oxaliplatin 130mgm
 2 intravenously on day
1 and capecitabine 1000mgm
 2 orally twice daily on days
1–14 in a 21-day cycle is comparable with other chemotherapy
regimens in metastatic or local–regional unresectable oeso-
phageal cancer. The frequency of grade 3/4 toxicity was low
Table 2 Haematological and non-haematological toxicities
(%) Grade 0 (%) Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%)
Anaemia 7 (14) 36 (70) 7 (14) 1 (2) —
Leucopenia 43 (84) 6 (12) 2 (4) — —
Neutropenia 45 (88) — 5 (10) 1 (2) —
Thrombocytopenia 31 (61) 15 (29) 5 (10) — —
Nausea 9 (18) 29 (57) 10 (19) 3 (6) —
Vomitus 21 (41) 20 (39) 6 (12) 4 (8) —
Anorexia 36 (71) 10 (19) 4 (8) 1 (2) —
Diarrhoea 23 (45) 23 (45) 4 (8) 1 (2) —
Lethargy 6 (12) 30 (59) 12 (23) 2 (4) 1 (2)
Hand–foot syndrome 42 (82) 3 (6) 4 (8) 2 (4) —
Polyneuropathy (sensory) 4 (8) 34 (67) 11 (21) 2 (4) —
Polyneuropathy (motor) 47 (92) 1 (2) 1 (2) 2 (4) —
Hyperbilirubinemia 39 (76) 8 (16) 3 (6) 1 (2) —
Data from 51 evaluable patients.
Oxaliplatin and capecitabine in oesophageal cancer
E van Meerten et al
1351
British Journal of Cancer (2007) 96(9), 1348–1352 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sand the QoL was maintained during the treatment. Because
this treatment is probably less toxic than cisplatin-based
therapy, with preservation of QoL during treatment, and
because it can be given on an outpatient basis, this regimen is a
viable treatment option in patients with advanced oesophageal
cancer.
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